WALTHAM, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today it is a sponsor of The Cancer Support Community’s symposium, “The Patient Voice: The First Year of the Cancer Experience Registry,” in recognition of National Breast Cancer Awareness Month. Radius is pleased to help be a sponsor of this patient-focused event.
The event was held on October 22, 2014 on the Cancer Support Community campus in West Fairmount Park, Philadelphia, PA. The symposium commemorates the release of the Annual Index Report based on the findings of the first year of the Cancer Experience Registry.
“We are delighted to help sponsor this important symposium designed to encourage discussion, learning and support amongst the cancer patient community,” according to President and CEO, Robert Ward of Radius Health.
The Cancer Support Community established the Cancer Experience Registry as a robust and enduring vehicle designed to engage individuals from across the country, identify trends and track their social and emotional needs over time, link them to other cancer patients and raise awareness of these findings. To date, there are over 7,000 cancer patients who have joined the Cancer Experience Registry and, of that, there are over 950 participants in a sub-registry for people living with metastatic breast cancer.
The information collected by the Cancer Experience Registry is used to positively impact the future of cancer care, develop programs and offer services to address the emotional and social needs of those affected by cancer. This has been shown to improve the quality of life and health outcomes of cancer survivors and their families.
“The support of Radius Health has helped make possible this important patient-powered symposium which has the capacity to engage the cancer community at large from across disciplines and perspectives. The overall goal of the symposium is to create a learning environment for the whole community – including patients, families, researchers, advocates and others,” said Kim Thiboldeaux, President and CEO of Cancer Support Community.
National Breast Cancer Awareness Month (NBCAM) is a collaboration of national public service organizations, professional medical associations and government agencies working together to promote breast cancer awareness, share information on the disease and provide greater access to services. October is designated as National Breast Cancer Awareness Month, but NBCAM is dedicated to raising awareness and educating individuals about breast cancer throughout the year.
Metastatic breast cancer is a form of advanced breast cancer, also commonly referred to as Stage 4 breast cancer, which occurs when breast cancer has spread to other parts of the body. There is no cure for metastatic disease, but it is considered treatable with a treatment goal of delaying the progression of symptoms.
About the Cancer Support Community
The mission of the Cancer Support Community (CSC) is to ensure that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. In 2009, The Wellness Community and Gilda’s Club joined forces to become the Cancer Support Community. The combined organization, with more than 50 years of collective experience, provides the highest quality social and emotional support for people impacted by cancer through a network of 50 licensed Affiliates, more than 120 satellite locations and vibrant online and telephone communities, touching more than one million people each year. www.cancersupportcommunity.org
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius’ lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.com
Help employers find you! Check out all the jobs and post your resume.
